CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0257 (clinicaltrials.gov NCT No: NCT01097018)
Title:A Phase III Randomized Double-Blind Study to Assess the Efficacy
and Safety of Perifosine Plus Capecitabine Versus Placebo Plus
Capecitabine in Patients with Refractory Advanced Colorectal
Cancer (Perifosine 343)
Principal Investigator:Cathy Eng
Treatment Agent:Capecitabine; Perifosine
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the combination of
perifosine (also called the study drug) and Xeloda® (capecitabine) can help to
control advanced colorectal cancer. The safety of this combination treatment
will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Colorectum
Phase of Study:Phase III
Treatment Agents:Capecitabine
Perifosine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Keryx / AOI Pharmaceuticals, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Cathy Eng
Dept:Gastrointestinal Medical Oncology
For Clinical Trial Enrollment:713-792-2828
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults